(HSIC) Henry Schein - Ratings and Ratios

Henry Schein, Inc. (NASDAQ:HSIC) is a global leader in delivering health care products and services to dental, medical, and alternate care practitioners. The company operates through three primary segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. Its product portfolio includes a wide range of dental and medical supplies, such as infection-control products, dental implants, pharmaceuticals, vaccines, and diagnostic tests. The company also offers financial services, education, and consulting to practitioners, as well as practice management software and e-services. Henry Schein serves customers in dental practices, laboratories, physician offices, ambulatory surgery centers, and government clinics. Founded in 1932, the company is headquartered in Melville, New York.

Henry Schein, Inc. (NASDAQ:HSIC) provides comprehensive solutions to health care professionals worldwide. Its operations span dental and medical products, including equipment, consumables, and specialty products. The company also manufactures and distributes dental implant and biomaterial products, as well as orthodontic and orthopedic solutions. Additionally, Henry Schein offers financial services, educational resources, and technology solutions to enhance practice efficiency. Its customer base includes dental and medical practitioners, laboratories, and institutional health care providers. With a strong presence in global markets, Henry Schein continues to expand its offerings through innovation and strategic partnerships.

Over the next three months, based on and , Henry Schein, Inc. (NASDAQ:HSIC) is expected to demonstrate stable performance. The stocks short-term moving averages (SMA 20: 65.77, SMA 50: 70.21) suggest a potential rebound from recent price levels (Last Price: 66.23). The ATR of 2.16 indicates moderate volatility, while the forward P/E of 13.35 signals undervaluation relative to its current P/E of 21.22. With a market cap of $7,930.20M and a P/S ratio of 0.63, the company is well-positioned for steady growth in the health care distribution sector. Its return on equity (RoE: 11.49%) further underscores its operational efficiency. Overall, the stock is expected to remain range-bound with upside potential driven by its fundamentals and industry outlook.